NTRK1 and cancer: Recent advances in cancer therapeutics targeting the EGFR/ErbB family of Receptor Tyrosine Kinases (RTKs) have shown promise in providing an alternate therapy with efficacy at least equivalent to that of chemotherapy in mutant forms of EGFR [1,2].